SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | n/a |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | -0.23 |
| Book Value / Share | -0.03 |
| Price / Book | n/a |
| NCAV ($M) | -0.24 |
| NCAV / Share | -0.03 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.95 |
| Current Ratio | 0.95 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 4.34 |
| Assets | 4.36 |
| Liabilities | 4.58 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -16.81 |
| Net Income | -10.01 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -16.43 |
| Cash from Investing | 0.00 |
| Cash from Financing | 7.02 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | RPC Pharma Ltd | 26.40 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 1,720 | 7,525 | 22.86 | |
| 1,180 | 4,786 | 24.66 | |
| 1,972 | 2,037 | 96.81 | |
| 100 | 295 | 33.90 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| AADI – Aadi Bioscience, Inc. | ABEO – Abeona Therapeutics Inc. |
| ABIO – ARCA biopharma, Inc. | ABVC – ABVC BioPharma, Inc. |
| ACB – Aurora Cannabis Inc. |
Financial data and stock pages provided by
Fintel.io